Adjuvant pegylated liposomal doxorubicin versus epirubicin sequential paclitaxel in triple-negative breast cancer: comparable efficacy with a distinct safety profile
In adjuvant therapy for TNBC, PLD sequential paclitaxel demonstrated comparable efficacy to epirubicin sequential paclitaxel. However, PLD exhibited a distinct and generally more favorable safety profile, except for specific toxicities such as hand-foot syndrome and mucositis. The developed nomogram may aid in individualized prognosis prediction.
Authors
- Xiaoxin Zheng (ORCID: https://orcid.org/0000-0002-4525-8123)
- Yong Qiang Shi
- H. Chen
- Quan Zhou
- Shaohong Yu
- Shuanglong Cai
- Xiaogeng Chen
- Tao Ma
- Xiuquan Lin
- Hong Sun
Institutions
- Academy of Medical Sciences (GB)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Lishui University (CN)
- Lishui Central Hospital (CN)
- National Center for Chronic and Noncommunicable Disease Control and Prevention (CN)
- Lishui City People's Hospital (CN)
- Fujian Provincial Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-04
- DOI
- https://doi.org/10.3389/fimmu.2026.1690888
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wenzhou Medical University
- Natural Science Foundation of Fujian Province
- Lishui University
- Fujian Medical University